^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Triple Negative Breast Cancer
    Drug:eganelisib (IPI-549) (PI3Kγ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Businesswire
    Title:

    Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

    Published date:
    09/29/2020
    Excerpt:
    ...the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy for the treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer (TNBC), in the first-line setting.
    Secondary therapy:
    Immune Checkpoint Inhibitors; Chemotherapy